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Abstract
The use of genetically modified mice, i.e. transgenic as well as gene knockout (KO) and knock-in mice, has become an
established tool to study gene function in many animal models for human diseases . However, a gene functions in a
particular genomic context. This implies the importance of a well-defined homogenous genetic background for the analysis
and interpretation of phenotypes associated with genetic mutations. By studying a Plasmodium chabaudi chabaudi AS
(PcAS) malaria infection in mice bearing a TLR9 null mutation, we found an increased susceptibility to infection, i.e. higher
parasitemia levels and increased mortality. However, this was not triggered by the deficient TLR9 gene itself. Instead, this
disease phenotype was dependent on the heterogeneous genetic background of the mice, which appeared insufficiently
defined as determined by single nucleotide polymorphism (SNP) analysis. Hence, it is of critical importance to study gene
KO phenotypes on a homogenous genetic background identical to that of their wild type (WT) control counterparts. In
particular, to avoid problems related to an insufficiently defined genetic background, we advocate that for each study
involving genetically modified mice, at least a detailed description of the origin and genetic background of both the WT
control and the altered strain of mice is essential.
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Introduction
The major histocompatibility complex (MHC) on human
chromosome 6 covers a large genomic region with a central role
in determining the degree of disease susceptibility. In this locus,
small gene polymorphisms, typically located in alleles in charge of
protein processing and presentation as well as immune regulation,
are associated with several human autoimmune diseases, e.g.
multiple sclerosis, type 1 diabetes and rheumatoid arthritis, but
also with infectious diseases, e.g. malaria [1–6]. Aside the MHC
having a major impact on immune phenotypes, many genes
outside this susceptibility locus contribute to immunomodulation.
This is increasingly recognized by genome-wide association studies
(GWAS) in which genes encoding cytokines, cytokine receptors
and pattern recognition receptors (PRRs, e.g. Toll-like receptors
(TLRs), RIG-I-like receptors (RLRs), Nod-like receptors (NLRs))
are identified to play small but definite effects that may synergize
[7,8]. In addition, single nucleotide polymorphisms (SNPs) in
TLRs are found to correlate with susceptibility to infectious
diseases [9]. For instance, polymorphisms in TLR1, TLR4 and
TLR9 are associated with an aggravated clinical status of malaria
during pregnancy [10,11]. Polymorphisms in TLR4 are also
reported to play a role in controlling the parasitemia level in
malaria [12]. Furthermore, in malaria, alleles associated with
sickle-cell anemia, thalassemias, and glucose-6-phosphate dehy-
drogenase deficiency confer protective effects, whereas polymor-
phisms in the TNF-a gene have been linked to increased risk of
cerebral malaria (CM) [13]. Hence, complex host genetics, in
addition to environmental factors, are invoked in defining
susceptibility or resistance against several diseases.
In malaria research, many groups attempted to examine the
role of TLRs by using TLR
2/2 mice. Both in human and
experimental malaria, enhanced TLR activation is suggested to
prime proinflammatory cytokine responses (IL-12, IFN-c, TNF-a),
which in turn can favor host hyperresponsiveness to TLR agonists
during acute malaria. Subsequently, excessive inflammation might
contribute to malaria pathology, such as fever, CM and anemia
[14,15]. Therapeutical treatment with TLR antagonists was found
to diminish TLR activation and to prevent the development of
experimental cerebral malaria (ECM) [16]. Tolerance to TLR
signaling, however, was observed in a murine malaria model at
later stages of infection and was paralleled by an anti-inflamma-
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immune system might reflect a mechanism to balance pro- and
anti-inflammatory responses to avoid severe pathology.
The fact that the phenotype of a single gene mutation is
frequently modulated by a large number of background genes has
been illustrated by Griffith et al., who have studied the role of TLR
signaling in the development of ECM [18]. It was shown that
knocking out MyD88 or TLR9 in the CM-susceptible Th1-
permissive C57Bl/6 background turns out into a resistant
phenotype, whereas in CM-resistant Th2-permissive Balb/c mice,
interruption of the TLR pathway by deleting MyD88 results in
development of CM and increased mortality. Thus, two congenic
strains carrying the same null mutation can have a divergent
phenotype dependent on their genetic background. This is,
however, not unique to malaria-related phenotypes [19–21].
Coban et al. also revealed that TLR2-, TLR9- and MyD88-
dependent signaling is essential in murine CM on a C57Bl/6
background [22]. However, controversies on the contribution of
the TLR cascade to the development of experimental CM
pathogenesis exist as several studies ascertain that murine CM is
independent of TLR signaling [23,24]. In addition, the route of
infection also appears to influence the effect of the TLR pathway
on CM [25].
Plasmodium spp. have been shown to contain ligands for TLRs.
Besides TLR2 that recognizes malarial glycosylphosphatidylinosi-
tol [26], TLR9 gained attention since hemozoin or malaria
pigment, which is a crystalline detoxification product of heme
formed in the food vacuole of parasites during hemoglobin
digestion, has been described as a ligand of TLR9 able to induce
immune activation [27,28]. However, it is still a matter of debate
whether hemozoin itself binds this receptor, whether malaria
pigment carries plasmodial DNA to TLR9 or whether the TLR9
ligand is a histone-DNA complex [29–32]. Recently, it was
discovered that several hemozoin effects are dependent on its
stable interaction with host fibrinogen and the activation of
receptors TLR4/integrin by this complex [33].
In this study, we attempted to further examine the role of TLR9
in a Plasmodium chabaudi chabaudi (PcAS) infection model. First, we
used a common practice strategy, by studying and comparing
commercial wild type mice from Janvier (WT(Jv)) with the
TLR9
2/2 mice that we originally received (OR). Subsequently,
the validity of this strategy was investigated by performing an
additional backcross and by in-depth investigation of the genetic
background of these mice. Our data demonstrate that phenotypic
differences observed between mutant and control mice can simply
result from the effect of background genes and this might lead to
misinterpretation of results.
Results
Infection-induced phenotypic differences between
WT(Jv) and TLR9
2/2(OR) are lost after one additional
backcross generation
The infection of C57Bl/6 WT mice with PcAS is characterized
by an acute primary peak of parasitemia around day 9–10,
followed by a chronic phase marked by one or two small
recrudescences around day 30 post infection (pi). Finally, the
parasite is cleared and mice survive the infection [34]. Since TLR9
is a crucial component connecting innate and adaptive immunity,
it was interesting to investigate the role of TLR9 in protective
immunity against blood-stage PcAS. The TLR9 genotype of each
mouse was confirmed by PCR (Figure S1). In first instance, we
compared the course of PcAS infection in the originally received
B6.TLR9
2/2(OR) mice and commercial inbred B6.WT(Jv) mice
and observed a phenotype in parasitemia. Primary parasitemia
peaked between 7 and 12 days pi and peak values of individual
mice were significantly higher in B6.TLR9
2/2(OR) mice
compared to B6.WT(Jv) mice (Figures 1A–B; p,0.01). During
the chronic stage of infection between day 20 and day 44 pi,
B6.TLR9
2/2(OR) mice suffered from 10-fold higher levels of
recrudescent parasitemia (median=10.1%) compared to the
B6.WT(Jv) controls, which had only small recrudescences
(median=0.09%) (Figure 1C; p,0.001). Moreover, infected
B6.TLR9
2/2(OR) mice became considerably more anemic
(Figure S2; p,0.001) and limited but significant mortality was
observed in large cohorts among these TLR9-deficient mice,
whereas B6.WT(Jv) mice were fully resistant to PcAS infection
(Figure 1D; p,0.01 by Log-rank (Mantel Cox) test). Hence,
although discrepant from other published data [15,35–38], the
B6.TLR9
2/2(OR) mice were less well protected against acute and
chronic parasitemia.
As antibody-dependent immunity is considered essential during
blood-stage malaria infection, particularly for the resolution of the
chronic stage of infection [39–42], we tried to explain antiparasite
immunity with known TLR9 effects on antibody responses [43,44]
(Figure S3). Our data suggested that IgM, IgG2b and IgG2c
antibodies might play a role in the protective immunity to control
acute and chronic stage PcAS infection, whereas IgG1 was
inversely correlated with parasite control. Serum transfer exper-
iments were performed and significant antiparasite activity was
observed only when immune sera were derived from commercial
B6.WT(Jv) mice and not from B6.TLR9
2/2(OR) mice (Figure
S4). The Th2-skewed antibody profile in B6.TLR9
2/2(OR) mice
together with the inability of B6.TLR9
2/2(OR) immune sera to
affect primary parasitemia levels caused the impression that TLR9
liganding assists in the generation of a protective antibody profile
essential for the acquisition of anti-malaria immunity. However,
this was in contradiction to the results published by Seixas et al.,
who showed that both parasitemia control and antibody
production were not affected by a TLR9 deletion [35].
To determine whether the observed difference in susceptibility
to PcAS infection between B6.WT(Jv) and B6.TLR9
2/2(OR) mice
was due to the inactivation of the TLR9 gene or to genetic and
phenotypic line differences unrelated to the targeted mutation,
B6.WT(Jv) and B6.TLR9
2/2(OR) mice were crossed and
heterozygous progeny were mated to obtain matched B6.WT
and B6.TLR9
2/2 lines. These additionally backcrossed
B6.TLR9
2/2(BC) mice and their B6.WT(BC) controls were
infected with 10
4 PcAS pRBCs and the course of parasitemia
was monitored. However, in contrast to our observations with the
B6.TLR9
2/2(OR) mice (Figures 1A–C), no significant differences
in the course of parasitemia between the B6.WT(BC) and
B6.TLR9
2/2(BC) mice were noticed (Figures 1E–G). Indeed,
acute as well as recrudescent peak parasitemia values between
both control and mutant lines were comparable in this experi-
mental setup (Figures 1F–G). In addition, all B6.TLR9
2/2(BC)
micesurvivedthe infection(Figure 1H),whereassome mortalitywas
observed in the B6.TLR9
2/2(OR) mice used in the initial
experimental setup (Figure 1D).
These data, however, reinforce the published ones [15,35–38]
and called for a reconsideration of the genetic background. SNPs,
the single most abundant class of genetic variation in mammals,
have become the markers of choice to distinguish inbred mouse
strains on a genetic basis.
Extensive SNP genotyping was performed by Charles River as
detailed in the Materials and Methods section. Fourteen samples
were tested: B6.WT (Jv, samples 1–4), B6.TLR9
2/2 (OR, samples
5–8), B6.WT (BC, samples 9–11) and B6.TLR9
2/2 (BC, samples
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2/2(BC) and B6.WT(BC)) abolishes the phenotypic differences in the course
of infection between B6.WT(Jv) and B6.TLR9
2/2(OR) mice. As detailed in materials and methods, B6.WT(Jv) mice were intercrossed with
B6.TLR9
2/2(OR) mice and heterozygotes (F1) were mated to obtain matched backcrossed B6.WT(BC) and B6.TLR9
2/2(BC) mice. The offspring were
used for experiments. B6.WT(Jv) (black circles), B6.TLR9
2/2(OR) (grey squares), B6.WT(BC) (open circles) and B6.TLR9
2/2(BC) (open squares) mice were
infected ip with 10
4 PcAS pRBCs. (A,E) The course of parasitemia was monitored for 44 days by microscopic examination of thin Giemsa-stained
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was confirmed by PCR (Figure S1). Although we started our
experiments with the certification that the B6.TLR9
2/2(OR) mice
were at least 10-fold backcrossed to an inbred C57Bl/6
background, the SNP analysis ascertained significant genetic
background differences in the B6.WT(Jv) versus B6.TLR9
2/2
(OR) mice. In essence, the B6.TLR9
2/2(OR) mice were definitely
not congenic to C57Bl/6 as these animals still had large regions of
129 DNA unlinked to the TLR9 gene. This 129 DNA originates
from the ‘129’-derived embryonic stem (ES) cells carrying the
targeted mutation. When considering only those SNPs that
differentiate between C57Bl/6 and 129, the analysis revealed an
average of 69% C57Bl/6 DNA in the B6.TLR9
2/2
(OR) mice (Figure 2; Table S1, samples 5–8). This indicates that
only a maximum of two backcross generations had occurred.
According to classic genetics, however, the average percentage of
the genetic material after backcrossing a 129 chimera with a
C57Bl/6 mouse for two generations is expected to be 75%. It
might be possible that continuous long-term inbreeding of the ‘two
generations backcrossed TLR9
2/2(OR) mice’ had favored a
positive selection for 129 genes, thereby increasing the percentage
of 129 DNA at the expense of C57Bl/6 DNA. The additional
backcross that we performed to produce matched control and
mutant lines increased the degree of C57Bl/6 DNA in the new
B6.TLR9
2/2(BC) mice by approximately 15% (Figure 2; Table
S1, samples 12–14), but also ‘‘generated’’ the new B6.WT(BC)
mice with a similar level of non C57Bl/6 DNA including 129
DNA (Figure 2; Table S1, samples 9–11).
Discussion
Genetic components determining host susceptibility to malaria
are complex, both in human and in mice [45]. Considerable
efforts have been made to identify the genes responsible for the
development of the disease [13]. In human malaria, for example,
control of parasitemia levels was found to be linked to a locus on
chromosome 5q31-q33 [46].
Approximately 99% of human genes have mouse homologs and
the gene order is highly conserved. Hence, the mouse has served as
an appropriate experimental model that allowed to dissect
complex genetic traits and to decipher immunopathological
pathways of several complex human diseases. Inbred mouse
strains are generated by at least 20 sequential generations of sibling
mating, which drives heterozygous loci to homozygosity and
increases the genetic uniformity of the line. After 20 generations of
inbreeding, on average 98.6% of the genome should be
homozygous. This enables researchers to conduct reproducible
experiments [47]. Several studies, however, highlight the impor-
tance of the genetic background of the mouse strain used to mimic
and investigate human disease phenotypes. This is illustrated by
inbred mouse models of malaria infection, in which the outcome is
dependent upon the genetic background of the host. Indeed,
C57Bl/6 mice are resistant to infection with PcAS, whereas A/J
mice succumb to infection due to uncontrolled parasitemia and
severe anemia accompanied by suppressed erythropoiesis [40,48–
50]. Quantitative trait locus (QTL) mapping studies in recombi-
nant congenic mouse strains have identified several Chabaudi
resistance (Char) loci on various chromosomes important in
controlling susceptibility to PcAS infection, and hence, underline
the complexity and multigenicity in parasite control [51–54].
In the last decade, the use of mice carrying engineered genetic
modifications has revolutionized the study of gene function.
However, these new techniques also have their drawbacks and
special care should be taken when the target genes are involved in
a complex network of interacting genes and biochemical processes,
which is the case for most immunological events. Indeed, the
phenotype of a mutation is often tuned by a particular genomic
context in which flanking genes as well as the genetic background
contribute to the induced mutation (reviewed by Sigmund et al.
[19]). As an example, outside of malaria research, an epidermal
growth factor null mutation on a CF-1 background results in early
embryonic death, whereas homozygous mutants on a 129/Sv
background die at mid gestation. On a CD-1 background, the
mutants survive for 3 weeks [20]. Hence, genes should not be
studied alone but have to be seen in an epistatic multigenic
network. It is extremely important to use congenic strains when
evaluating phenotypes resulting from gene manipulation [19].
Congenic strains are defined as two inbred strains which are
genetically identical, except for the targeted gene and its flanking
region [55,56]. Eliminating the confounding effects of background
genes will improve the understanding of gene function. Most
commonly used ES cell lines for gene targeting are derived from
strain 129. Using traditional backcrossing methods, the 129
genome is progressively diluted. At least 7 generations of
backcrossing to a maintenance inbred strain (usually C57Bl/6)
are required to establish congenic lines with more than 99%
genetic homogeneity. However, the region flanking the mutated
gene still contains 129 DNA. It is recommended to characterize
knockout phenotypes on several different and clearly defined
Figure 2. TLR9
2/2(OR) mice are not congenic to the C57Bl/6
inbred line. The average percentage of C57Bl/6 DNA in each mouse
line was determined by monitoring of the genetic background via SNP
markers (Table S1). The bars represent the mean 6 SEM. B6.WT(Jv) and
B6.TLR9
2/2(OR), n=4; B6.WT(BC) and B6.TLR9
2/2(BC), n=3.
doi:10.1371/journal.pone.0027131.g002
blood smears. (B,F) Since not all mice reached their maximum peak parasitemia on the same day, the highest parasitemia of each individual mouse
between day 7 and 12 was selected as peak parasitemia and indicated as a single dot. The horizontal lines indicate the group medians. (C,G) Since
the timing of the recrudescences varied significantly between 20 and 44 days pi, the peak parasitemia values during recrudescences between day 20
and day 44 pi are shown and represented as single dots. The horizontal lines indicate the group medians. (D,H) Survival was monitored until 44 days
pi in the four different groups. (A–C) Data are representative of more than three independent experiments with at least five mice per group in each
experiment. (D) Data are a compilation of several experiments with at least five mice per group. (E–H) Data are a compilation of two independent
experiments with at least seven mice per group at each time point. ns, not significant. The numbers of mice (n) in each group are depicted in the
graph legend. **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0027131.g001
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models, the use of co-isogenic lines, defined as two inbred strains
that carry different alleles of only one gene but which are
otherwise genetically identical, will overcome the flanking gene
problem (use of ES cells from desired strain) [19,57–61].
An additional hurdle is that, although inbred strains are forced
to homozygosity and genetic uniformity, minor variations within
an inbred strain have been found. Moreover, when inbred strain
colonies are separated and raised in a different environment or at
another laboratory, substantial substrain differences may occur.
The use of different substrains from the same inbred strain can
hamper the reproducibility and interpretation of experimental
results. Genetic variation arises by accidental genetic contamina-
tion due to errors in animal management, or by genetic drift.
Genetic drift favors fixation of new mutations or the elimination of
residual heterozygosity and leads to changes in inbred strains over
time or between inbred lines that were physically separated (i.e.
substrains). Commercial breeders have specific breeding programs
to slow down genetic drift, e.g. the Genetic Stability Program
(GSP) of The Jackson Laboratory [62–64]. It is essential to
acknowledge the phenomena of spontaneous mutations and
genetic drift regarding the use of WT mice from a commercial
breeder or other sources as ‘controls’ when designing studies with
genetically engineered mice. A solution may be to intercross both
inbred WT control mice with KO mice and use enough WT and
KO progeny from F2 for experimental setup. Applying this
strategy will scramble the genetic background of both mouse lines
and even out a large part of small line variations.
The data presented in this study highlight the importance of a
well-defined homogenous genetic background - which should be as
similar as possible between the control and the mutant line - in the
analysis of the effect of a TLR9 deletion on the parasitemia course
during a PcAS infection. In our first experimental setup, an
increased susceptibility against PcAS infection was observed in
mice lacking TLR9, which were originally received as being at
least 10 times backcrossed to the inbred C57Bl/6 strain. However,
after backcrossing B6.TLR9
2/2(OR) mice into B6.WT(Jv) for one
additional generation, the TLR9 KO-associated phenotype was
lost. Reassessment of the genetic identity of the original
B6.TLR9
2/2(OR) mice by analyzing 384 mouse SNP markers
revealed a maximum of two backcross generations resulting in a
heterogeneous genetic background composed of C57Bl/6 DNA
together with large regions of 129 DNA unlinked to the TLR9
gene. Some of the B6.TLR9
2/2(BC) mice, however, still displayed
high recrudescent parasitemia values comparable to those
observed in the insufficiently backcrossed B6.TLR9
2/2(OR) mice
used in the initial setup. A possible explanation is that, due to
random genetic recombination in meiosis, e.g. by independent
assortment of chromosomes and chromosomal crossovers, some of
the new B6.TLR9
2/2(BC) mice, which were still not congenic
after an extra backcross, might still contain the 129 genes that
contributed to the increased susceptibility for PcAS infection.
Indeed, genetic analyses of hybrids of various inbred mouse strains
with different susceptibilities to P. chabaudi have revealed that
several loci on several chromosomes are associated with
susceptibility/resistance to high parasitemia (reviewed in [49]). A
similar hypothesis can also be applied to the observed increased
recrudescent parasitemia values observed in some of the new
B6.WT(BC) mice. Indeed, these B6.WT(BC) mice have gained
some 129 DNA at the expense of C57Bl/6 genetic material.
Rather than being induced simply by the TLR9 null mutation, the
observed increased susceptibility phenotype might be due
primarily to ‘contaminating’ 129 DNA. This theory is indeed
supported by the fact that the 129 mouse strain is also susceptible
for PcAS infection [49]. A third possibility might be that the
enhanced susceptibility phenotype is induced by epistatic interac-
tions of uncharacterized background genes, originating from DNA
of 129 and C57Bl/6 mouse strains. An illustration of a phenotype
induced by the combined effect of both 129 and C57Bl/6 genetic
material is provided by Bygrave et al. [65]. These authors have
shown that, in the absence of any gene-targeted mutations, the
interplay between loci of 129 and C57Bl/6 mice was sufficient to
cause humoral autoimmunity. Hence, the additional intercross
between B6.WT(Jv) and B6.TLR9
2/2(OR) mice has shuffled their
genetic background and evened out the phenotypic line differences
which were probably due to 129 DNA and unrelated to the TLR9
deletion. In accordance herewith, Seixas et al. did also not observe
any effect of TLR9 deficiency on the course of parasitemia and
antibody profiles during a PcAS infection [35].
Guided by the results presented in this study and in addition to
several other reports that stress complications in the experimental
setup of knockout studies [59–61], it has to be acknowledged that
the poor description of the mouse genetic constitution in many
published reports is in sharp contradiction with the rules of
classical genetics. Table 1 lists the experimental setup and results
of 5 studies on the effect of a TLR9 deletion in a PcAS infection. In
addition, 13 studies on the role of TLR9 in other malaria models
are included for further comparison. From this, it is clear that
often insufficient information on the genetic setup of the used KO
and control WT mice is provided. This is in part due to the free
circulation of many KO mouse strains between many laboratories
worldwide, sometimes resulting in the loss of the correct
information on the genetic background. In addition, the WT
mice are often obtained from a commercial breeder, which raises
concerns about the use of these mice as controls. Indeed, even if
the KO strain is sufficiently backcrossed into an inbred line, it is
important to use non-transgenic control mice derived from the
same inbred line, as this will minimize strain differences due to
genetic drift. Alternatively, intercrossing of the control WT mice
and the KO mice is convincing as a final confirmation of the
obtained results, if in vivo neutralization of the target protein is
practically unachievable. More advanced approaches to study
gene function are the ‘conditional knockout’ models or the use of
ES cells from the required strain [59]. The reason behind the
discrepant results summarized in Table 1 concerning the role of
TLR9 in malaria pathogenesis might be due to the distinct
experimental designs of the mouse studies by different research
groups. This problem of genetic background effects may not be
limited to the role of TLR9 in PcAS infections, but may also be
relevant for other studies with other mouse models, even not
related to malaria. Furthermore, besides host genetics, other
factors may be invoked in determining susceptibility to PcAS and
other malaria strains, i.e. parasite substrains and genetics, breeding
and housing conditions, intestinal flora, food, sex, age and also the
source and route of infection [25,66–69].
As a conclusion, in phenotype studies of genetically modified
animals, a significant impact on the phenotype may come from the
culmination of small effects by many genes that may be different
between wild type and modified animals. These differences may be
minimized by a sufficient number of backcrosses. Ideally, gene
function has to be studied between congenic or even co-isogenic
strains. For the sake of reproducibility, all reports concerning
genetic experiments must include detailed information on the
origin and the genetic background of the studied animals.
Genetic Context Confounds Malaria TLR9 Phenotype
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2/2 mice in experimental malaria infections.
CONTROL STRAIN KNOCKOUT STRAIN TLR9 knockout phenotype Ref.
Source Breeding information Source
N6 of backcross
generations to the
WT background
Plasmodium chabaudi AS
B6.WT(?) + PcAS undefined B6.TLR9
2/2(?)+PcAS undefined no difference in parasitemia, in
body weight and in temperature,
Q production of IFN-c by
splenocytes on day 8 pi
[36]
B6.WT (local breeding
facility) + PcAS
undefined (*pure local
C57Bl/6 line)
B6.TLR9
2/2
(Prof. Akira,Japan)
a+PcAS
undefined (*at least
8–96on local inbred
line)
no difference parasitemia, no
difference in the alterations in
splenic microarchitecture
[37]
B6.WT(JL) (DCs) + PcAS according to commercial
breeder strategy [75]
B6.TLR9
2/2 (Prof. Akira,Japan)
a
(DCs)+PcAS
at least 86 no difference in parasitemia, Q
TLR upregulation, Q production
of IFN-c/IL-12 by splenocytes/ DCs,
q resistance against LPS-induced
mortality
[15]
B6.WT (?, *local breeding
facility) (pDCs) + PcAS
undefined (*pure local
C57Bl/6 line)
B6.TLR9
2/2 (Prof. Akira,Japan)
a
(pDCs)+PcAS
106 Q IFN-c production in co-culture
of pDC+iRBC, Q IFN-c mRNA in
pDC on day 3 pi, no difference in
parasitemia, body weight and
temperature
[38]
B6.WT (local breeding
facility) (DCs) + PcAS or
PbANKA
undefined B6.TLR9
2/2 (Prof. Akira,Japan)
a
(DCs)+PbANKA or PcAS
undefined Q DC activation by parasites, no
nuclear translocation of NF-kBi n
DCs, no difference in parasitemia
(PcAS), Q in vivo activation of splenic
DCs, q IgM on day 10 pi (PcAS)
[35]
Plasmodium berghei ANKA
B6.WT(?) + PbANKA undefined B6.TLR9
2/2
(Prof. Akira,Japan)
a+PbANKA
at least 106 Q macrophage response to pRBCs,
no difference in parasitemia, in lung
and hepatic pathology, in CM
development and in survival
[23]
B6.WT(JL) + PbANKA according to commercial
breeder strategy [75]
B6.TLR9
2/2(?)+PbANKA at least 76 no difference in parasitemia,
q survival, Q CM
[18]
B6.WT (CLEA, Japan) +
PbANKA
according to commercial
breeder strategy [76]
B6.TLR9
2/2
(Prof. Akira,Japan)
a + PbANKA
at least 86 no difference in parasitemia,
q survival, QCM
[22]
B6.WT (?, *local breeding
facility) + PbANKA
undefined (*pure C57Bl/6
from local breeding facility)
TLR2/4/9
2/2
(Kirschning,Munich)
b + PbANKA
mixed
(129SVxC57Bl/6)
no difference in parasitemia,
CM development and survival
[24]
Plasmodium yoelii
B6.WT (Kyudo,Japan) + P.
yoelii
undefined B6.TLR9
2/2
(Prof. Akira,Japan)
a + P. yoelii
at least 156 partial resistance to lethal infection
(parasitemia, survival), Q activation
of Tregs by DCs, q activation of
CD4
+ T cells
[68]
Balb/c.WT (CLEA Japan) +
immunization with
baculovirus-based
PyMSP119 + P. yoelii 17XL
according to commercial
breeder strategy [76]
Balb/c.TLR9
2/2 (Prof.
Akira,Japan) + immunization
with baculovirus-based
PyMSP119 + P. yoelii 17XL
undefined vaccine induced protection
abolished, q Th2 immune responses
[77]
Parasite components
B6.WT (CLEA Japan): DCs +
schizont extracts
according to commercial
breeder strategy [76]
B6.TLR9
2/2 (Prof. Akira,Japan)
a:
DCs+schizont extracts
86 Q schizont-induced DC activation [27]
B6.WT (?, *CLEA Japan)
(DCs) + n/sHz
undefined (*according to
commercial breeder
strategy [76])
B6.TLR9
2/2 (Prof. Akira,Japan)
a
(DCs) + n/sHz
undefined
(*at least 86)
Q innate immune activation
by n/sHz
[28]
B6.WT(JL): DCs + n/sHz according to commercial
breeder strategy [75]
B6.TLR9
2/2 (Prof. Akira,Japan)
a:
DCs + n/sHz
more than 106
(genetic background
analyzed by
microsatellite analysis
(Charles River
Laboratories))
Q innate immune activation by
plasmodial DNA on Hz
[31]
B6.WT(JL) (macrophages)
+ sHz
according to commercial
breeder strategy [75]
B6.TLR9
2/2 (Prof. Akira,Japan)
a
(macrophages) + sHz
96 no difference in inflammatory
response to sHz
[78]
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(Additional information on the experimental procedures is
provided in supporting Text S1)
Ethical statement
All animal experiments were conducted with the approval of the
Institutional Ethics Committee under license LA121251 (Belgium)
for animal welfare.
Mice and experimental infections
Male and female C57Bl/6 wild type (B6.WT) mice were
purchasedfrom Janvier (Jv,Heverlee, Belgium).B6.TLR9 knockout
mice (B6.TLR9
2/2) were originally generated as described
previously [70] in the laboratory of Prof. S. Akira (Department of
Host Defense, Research Institute for Microbial Diseases, Osaka
University, Osaka, Japan). They were obtained from Prof. S.
Magez [Laboratory for Cellular and Molecular Immunology,
Free University of Brussels (VUB), Belgium]. After receiving
B6.TLR9
2/2 breeding pairs, these mice were bred and maintained
in the conventional animal facility St. Rafae ¨l of the Rega Institute
for Medical Research (University of Leuven, Leuven, Belgium).
From each individual mouse, the TLR9 genotype was confirmed by
PCR. B6.WT and B6.TLR9
2/2 mice, 8–12 weeks old, were age-
and sex-matched in all experiments. These mice are denoted as
B6.WT(Jv) and B6.TLR9
2/2(OR) mice.
To generate non-transgenic littermates as B6.WT controls, an
intercross breeding strategy was performed. B6.WT(Jv) mice were
coupled with B6.TLR9
2/2(OR) mice to yield F1 heterozygotes.
The latter were inter-mated to obtain additionally backcrossed
TLR9
2/2mice and matched WT controls in the F2 generation.
For each individual mouse, the genotype was confirmed by PCR.
To obtain a reasonable number of mice required for experimental
setups, breeding pairs of B6.WT and B6.TLR9
2/2 mice from the
F2 generation were assembled. Henceforth, these additionally
backcrossed B6.TLR9
2/2 mice and their matched B6.WT
controls were marked as B6.TLR9
2/2(BC) and B6.WT(BC) mice.
Mice were infected intraperitoneally (ip) with blood containing 10
4
Plasmodium chabaudi chabaudi clone AS (PcAS) parasitized red blood
cells (pRBCs) (a kind gift of the late Prof. Dr. D. Walliker,
University of Edinburgh, Scotland, U.K.). 10
4 pRBCs as infectious
dose was previously used by our laboratory and also by others
[71–74]. Mice received high energy food and drinking water was
supplied with para-amino benzoic acid (PABA) to improve in vivo
parasite growth. Parasitemia of individual mice was monitored
microscopically on Giemsa-stained blood smears.
Background strain characterization testing via Single
Nucleotide Polymorphisms (SNP) markers
Background strain characterization was performed at Charles
River (Charles River Genetic Testing Services, Troy, NY, USA).
Mouse tissue samples were tested with a background strain
characterization panel to evaluate strain line purity. The panel
consisted of 384 SNP markers. The SNP markers were spread
across the 19 mouse autosomes and the X chromosome at about
7 Mbp intervals and were polymorphic between various strains of
mice. In particular, 199 SNPs were polymorphic between C57Bl/
6 and 129. An array of inbred and hybrid controls were also
analyzed along with the samples. From 4 B6.WT(Jv), 4
B6.TLR9
2/2(OR), 3 B6.WT(BC) and 3 B6.TLR9
2/2(BC) mice,
tail DNA was prepared using the Nucleospin Tissue Kit
(Clontech Laboratories, Mountain View, CA, USA) on a Coulter
Biomek FX robotic system (Beckman Coulter, Brea, CA, USA).
After verifying yield on a 1% agarose gel or a NanoDrop
Spectrophotometer, the DNA was diluted to 20–40 ng/mlw i t h
distilled H2O (DNase and RNase free, Gibco, Invitrogen,
Carlsbad, CA, USA). Subsequently, the DNA was loaded into
OpenArray chips (Applied Biosystems, Foster City, CA, USA)
containing the Taqman primers and probes for the 384 SNP
markers. The two possible allele-specific probes were labeled with
reporter dyes VIC or FAM and contained a nonfluorescent
quencher.
Each reaction was performed in a volume of 33 nanoliters in a
separate through-hole on the array. The array containing the
Taqman SNP assays was cycled in a Hybaid thermal cycler as
follows: 1 cycle of 10 minutes at 91uC; 49 cycles of 23 seconds at
51uC, 30 seconds at 53.5uC, 13 seconds at 54.5uC, 22 seconds at
97uC and 7 seconds at 92uC; 1 cycle of 5 minutes at 20uC.
CONTROL STRAIN KNOCKOUT STRAIN TLR9 knockout phenotype Ref.
Source Breeding information Source
N6 of backcross
generations to the
WT background
B6.WT (?, *CLEA Japan)
+ Pf crude extract or
+ sHz
undefined (*according to
commercial breeder
strategy [76])
B6.TLR9
2/2 (Prof. Akira,Japan)
a +
Pf crude
extract or + sHz
undefined
(*at least 86)
Q adaptive immune responses after
Pf crude extract immunization, no
difference in potent adjuvanticity
of sHz
[30]
B6.WT(JL): DCs + parasite
components
according to commercial
breeder strategy [75]
B6.TLR9
2/2 (Prof. Akira,Japan)
a:
DCs + parasite components
undefined Q activation of DCs by MZs and
iRBCs
[79]
B6.WT (?, *JL): DCs +
polynucleosomes
undefined (*according to
commercial breeder
strategy [75])
B6.TLR9
2/2( Prof. Akira,Japan):
DCs + polynucleosomes
undefined (*several x) little or no activation of DCs by
polynucleosomes
[32]
aGenerated by Hemmi et al. [70].
bGenerated by Yasuda et al. [80].
*Personal communication.
q, increased; Q, decreased; B6, C57Bl/6; DCs, dendritic cells; CM, cerebral malaria; (p)DCs, (plasmacytoid) dendritic cells; (n/s)Hz, (natural/synthetic) hemozoin; iRBCs,
infected red blood cells; JL, Jackson Laboratory; MZs, merozoites; NF-kB, nuclear factor k-light-chain-enhancer of activated B cells; PbANKA, Plasmodium berghei ANKA;
PcAS, Plasmodium chabaudi chabaudi AS; Pf, Plasmodium falciparum; PyMSP119, Plasmodium yoelii 19 kDa carboxyl terminus of merozoite surface protein 1; TLR9, toll-
like receptor 9; Tregs, regulatory T cells.
doi:10.1371/journal.pone.0027131.t001
Table 1. Cont.
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(corresponding to the two possible SNP alleles) were quantified by
analyzing the array in an OpenArray Imager. Fluorescence data
were analyzed using the OpenArray SNP Genotyping Analysis
software (Applied Biosystems). Genotyping data were exported to
Microsoft Excel, sorted to place the markers in chromosomal
order, and pasted into a strain-specific scoring template to convert
the alleles present in each sample to numerical values. Markers
homozygous for the expected allele in the background to be
quantified were scored as ‘‘1’’. Markers heterozygous for the
expected allele and another allele were scored as ‘‘0.5’’. Markers
homozygous for another allele were scored as ‘‘0’’. The score for
each marker was averaged to calculate the percent of the strain of
interest in the background.
Statistical analysis
Data are presented as scatter dot plots with the line indicating
the median. Using the GraphPad Prism 5 software (GraphPad
Software, San Diego, CA, USA), the nonparametric Mann-
Whitney U-test was applied to determine the statistical
significance of the observed differences between two groups.
Survival was analyzed by the Log-rank (Mantel Cox) Test.
Differences were considered statistically significant when p,0.05
(two-tailed).
Supporting Information
Text S1 Online supporting results and supporting
materials and methods. Discussion on the results of figure
S3 (antibody levels) and figure S4 (antibody transfer experiment).
Detailed information on the supporting materials and methods.
(XLSX)
Figure S1 Genotype confirmation by PCR followed by
DNA separation and visualization on an agarose Flash-
Gel DNA cassette. Genomic DNA was extracted from mouse
tail samples as detailed in the supporting Text S1. The TLR9
knockout (upper gel) versus WT (lower gel) genotype was detected
by PCR and the amplified products were separated and visualized
on a 1.2% agarose FlashGel DNA cassette. A FlashGel DNA
marker was also loaded on the gel. Both WT and TLR9
2/2 bands
have a length of approximately 340 bp.
(TIF)
Figure S2 B6.TLR9
2/2(OR) mice suffer from signifi-
cantly more anemia than their B6.WT(Jv) counterparts
during PcAS infection. Between day 8 and day 16 pi, 10 mlo f
blood was taken from the tail vein and with the use of the ‘SDS-
haemichome method’, the concentration of hemoglobin was
measured colorimetrically in B6.WT(Jv, black circles) and
B6.TLR9
2/2(OR, grey squares) mice. From each individual
mouse, values of the lowest hemoglobin concentration after
primary peak parasitemia are presented. The dashed line
represents the hemoglobin level in naive mice, which is
approximately 14 g/dl. The hemoglobin levels were restored to
normal both in B6.WT(Jv) and B6.TLR9
2/2(OR) mice around
day 16 pi (data not shown). The horizontal lines indicate the group
medians. Data are representative for 3 independent experiments
with at least 5 mice per group for each experiment. The numbers
of mice (n) in each group are depicted in the graph legend. **,
p,0.01; ***, p,0.001.
(TIF)
Figure S3 Altered IgM and IgG subtype levels after PcAS
infection in B6.TLR9
2/2(OR) vs. B6.WT(Jv) mice.
B6.WT(Jv, black circles) and B6.TLR9
2/2(OR, grey squares)
mice were infected ip with 10
4 PcAS pRBCs and heparinized
plasma samples were collected at 0, 21 and 42 days pi. The levels
of IgM (A), IgG (B) and IgG subclasses IgG2c (C), IgG2b (D) and
IgG1 (E) in naive and infected B6.WT(Jv) and B6.TLR9
2/2(OR)
were determined by ELISA and compared to a laboratory
standard as detailed in the supporting Text S1. Horizontal lines
indicate the group medians and each dot represents data from a
single animal. Data are a compilation of two independent
experiments with at least five mice per infected group at each
time point. The numbers of mice (n) in each group are depicted in
the graph legend. *, p,0.05; **, p,0.01; ***, p,0.001.
(TIF)
Figure S4 Transfer of immune serum from B6.TLR9
2/2
(OR) mice did not affect the course of parasitemia in
B6.WT(Jv) mice. Naive B6.WT(Jv) mice were either sham-
treated (black circles) or treated ip with 200 ml immune serum (d21
pi) from B6.WT(Jv) (open circles) or B6.TLR9
2/2(OR) (grey
circles) mice followed immediately by infection with 10
4 PcAS
pRBCs. The course of parasitemia was monitored for 44 days by
microscopic examination of Giemsa-stained thin blood smears.
The horizontal lines indicate the group medians and each dot
represents data from a single animal. Data are a compilation of
two independent experiments with at least five mice per group at
each time point. The numbers of mice (n) in each group are
depicted in the graph legend. ***, p,0.001.
(TIF)
Table S1 Background strain characterization via SNP
markers. The genetic background of the mice was determined
by analysis of 384 SNPs. The results for 4 B6.WT(Jv), 4
B6.TLR9
2/2(OR), 3 B6.WT(BC) and 3 B6.TLR9
2/2(BC) are
compared with the profiles of one pure C57Bl/6 and one pure 129
mouse. The location of the TLR9 gene on chromosome 9
(106,125 Kbp–106,132 Kbp) is shaded in grey. All loci that do not
discriminate between C57Bl/6 and 129 are excluded (shaded in
blue). Vs and Fs are the allele names (refers to VIC and FAM
respectively). 1=homozygous C57Bl/6; 0.5=heterozygous for
C57Bl/6 allele (green); 0=homozygous for non C57Bl/6 allele
(yellow). Percentage of C57Bl/6 DNA and average % C57Bl/6
DNA in each group is indicated at the bottom of the sheet.
(DOC)
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